The Good Brigade/DigitalVision via Getty Images In recent years, you won't find many names that have done worse than cell programming and biosecurity company Ginkgo Bioworks (NYSE:DNA). The company has continued to miss lofty revenue growth targets, leading to its shares losing almost all of their value. Now that management is trying to turn things around and two major negative catalysts are behind us, it's time to see if this company can finally get on track. Previous coverage of the name I've been bearish ...